This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.

Seralutinib (GB002)

TORREY TLR PLS

See More

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Our goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.

program
discovery
phase 1
phase 2
phase 3
+

Seralutinib (GB002) –
Pulmonary Arterial Hypertension

Inhaled PDGFR, CSF1R, c-KIT inhibitor
Phase 3 ready

clinical trials

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Arterial Hypertension
Phase: Phase 3 Ready
Description: The primary objective for this trial is to determine the effect of GB002 on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 on improving exercise capacity in this population.

recent posters and publications

TORREY TLR PLS

ATS - May 2023

view more publications